Global Brain Tumor Treatment

Brain Tumor Treatment Comprehensive Study by Treatment (Surgery, Radiation Therapy, Radiosurgery, Chemotherapy, Targeted Drug Therapy), End-user (Hospitals, Clinics, Ambulatory Surgery Centres), Diagnosis (Imaging Tests, Neurological Exam, Biopsy, Others), Tumor Type (Chordomas, Craniopharyngiomas, Astrocytomas, Hemangioblastomas, Others) Players and Region - Global Market Outlook to 2026

Brain Tumor Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Brain Tumor Treatment?
A brain tumor is a group of abnormal cells that grow in or around the brain. It can directly destroy healthy brain cells and can damage healthy cells by crowding other parts of the brain and causing inflammation, brain swelling and pressure within the skull. It may be malignant or benign. The treatment of the brain tumor depends upon the type, size and location of the tumor as well as the health of the patient. It involves surgery, radiation therapy, radiosurgery, chemotherapy and targeted drug therapy.

The market study is broken down and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Brain Tumor Treatment market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Genentech U.S.A (United States), Bristol Myers Squibb (United States), Roche Holding AG 9Switzerland), AstraZeneca plc (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Antisense Pharma (Australia), Merck & Co.,Inc. (United States), Macleods Pharmaceutical Limited (India) and Mankind Pharma (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Dr. Reddys Laboratories Ltd. (India).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Brain Tumor Treatment market by Type, Application and Region.

On the basis of geography, the market of Brain Tumor Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Surgery will boost the Brain Tumor Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Brain Tumor Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Imaging Tests will boost the Brain Tumor Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Tumor Type, the sub-segment i.e. Chordomas will boost the Brain Tumor Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In January 2019, Bristol-Myers Squibb Company and Celgene Corporation has announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash. The transaction will create a leading focused specialty biopharma company well-positioned to address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities.



Market Trend
  • Growing Focus on Preventive Healthcare

Market Drivers
  • Increased Prevalence of Brain Tumors
  • Increased Consumer Awareness about Cancers
  • Technological Advancements in the Field of Medical Science

Opportunities
  • Growing Number of Regulatory Approvals
  • Huge Investments by Major Players

Restraints
  • Side Effects Associated with the Treatment

Challenges
  • Less Awareness in Under Development Countries


Key Target Audience
Brain Tumor Treatment Manufacturers, Research Professionals, Emerging Companies, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Treatment
  • Surgery
  • Radiation Therapy
  • Radiosurgery
  • Chemotherapy
  • Targeted Drug Therapy

By End-user
  • Hospitals
  • Clinics
  • Ambulatory Surgery Centres

By Diagnosis
  • Imaging Tests
  • Neurological Exam
  • Biopsy
  • Others

By Tumor Type
  • Chordomas
  • Craniopharyngiomas
  • Astrocytomas
  • Hemangioblastomas
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Brain Tumors
      • 3.2.2. Increased Consumer Awareness about Cancers
      • 3.2.3. Technological Advancements in the Field of Medical Science
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness in Under Development Countries
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Tumor Treatment, by Treatment, End-user, Diagnosis, Tumor Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Brain Tumor Treatment (Value)
      • 5.2.1. Global Brain Tumor Treatment by: Treatment (Value)
        • 5.2.1.1. Surgery
        • 5.2.1.2. Radiation Therapy
        • 5.2.1.3. Radiosurgery
        • 5.2.1.4. Chemotherapy
        • 5.2.1.5. Targeted Drug Therapy
      • 5.2.2. Global Brain Tumor Treatment by: End-user (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgery Centres
      • 5.2.3. Global Brain Tumor Treatment by: Diagnosis (Value)
        • 5.2.3.1. Imaging Tests
        • 5.2.3.2. Neurological Exam
        • 5.2.3.3. Biopsy
        • 5.2.3.4. Others
      • 5.2.4. Global Brain Tumor Treatment by: Tumor Type (Value)
        • 5.2.4.1. Chordomas
        • 5.2.4.2. Craniopharyngiomas
        • 5.2.4.3. Astrocytomas
        • 5.2.4.4. Hemangioblastomas
        • 5.2.4.5. Others
      • 5.2.5. Global Brain Tumor Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Brain Tumor Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genentech U.S.A (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol Myers Squibb (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG 9Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Antisense Pharma (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co.,Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Macleods Pharmaceutical Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mankind Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Brain Tumor Treatment Sale, by Treatment, End-user, Diagnosis, Tumor Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Brain Tumor Treatment (Value)
      • 7.2.1. Global Brain Tumor Treatment by: Treatment (Value)
        • 7.2.1.1. Surgery
        • 7.2.1.2. Radiation Therapy
        • 7.2.1.3. Radiosurgery
        • 7.2.1.4. Chemotherapy
        • 7.2.1.5. Targeted Drug Therapy
      • 7.2.2. Global Brain Tumor Treatment by: End-user (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgery Centres
      • 7.2.3. Global Brain Tumor Treatment by: Diagnosis (Value)
        • 7.2.3.1. Imaging Tests
        • 7.2.3.2. Neurological Exam
        • 7.2.3.3. Biopsy
        • 7.2.3.4. Others
      • 7.2.4. Global Brain Tumor Treatment by: Tumor Type (Value)
        • 7.2.4.1. Chordomas
        • 7.2.4.2. Craniopharyngiomas
        • 7.2.4.3. Astrocytomas
        • 7.2.4.4. Hemangioblastomas
        • 7.2.4.5. Others
      • 7.2.5. Global Brain Tumor Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Tumor Treatment: by Treatment(USD Million)
  • Table 2. Brain Tumor Treatment Surgery , by Region USD Million (2015-2020)
  • Table 3. Brain Tumor Treatment Radiation Therapy , by Region USD Million (2015-2020)
  • Table 4. Brain Tumor Treatment Radiosurgery , by Region USD Million (2015-2020)
  • Table 5. Brain Tumor Treatment Chemotherapy , by Region USD Million (2015-2020)
  • Table 6. Brain Tumor Treatment Targeted Drug Therapy , by Region USD Million (2015-2020)
  • Table 7. Brain Tumor Treatment: by End-user(USD Million)
  • Table 8. Brain Tumor Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 9. Brain Tumor Treatment Clinics , by Region USD Million (2015-2020)
  • Table 10. Brain Tumor Treatment Ambulatory Surgery Centres , by Region USD Million (2015-2020)
  • Table 11. Brain Tumor Treatment: by Diagnosis(USD Million)
  • Table 12. Brain Tumor Treatment Imaging Tests , by Region USD Million (2015-2020)
  • Table 13. Brain Tumor Treatment Neurological Exam , by Region USD Million (2015-2020)
  • Table 14. Brain Tumor Treatment Biopsy , by Region USD Million (2015-2020)
  • Table 15. Brain Tumor Treatment Others , by Region USD Million (2015-2020)
  • Table 16. Brain Tumor Treatment: by Tumor Type(USD Million)
  • Table 17. Brain Tumor Treatment Chordomas , by Region USD Million (2015-2020)
  • Table 18. Brain Tumor Treatment Craniopharyngiomas , by Region USD Million (2015-2020)
  • Table 19. Brain Tumor Treatment Astrocytomas , by Region USD Million (2015-2020)
  • Table 20. Brain Tumor Treatment Hemangioblastomas , by Region USD Million (2015-2020)
  • Table 21. Brain Tumor Treatment Others , by Region USD Million (2015-2020)
  • Table 22. South America Brain Tumor Treatment, by Country USD Million (2015-2020)
  • Table 23. South America Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 24. South America Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 25. South America Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 26. South America Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 27. Brazil Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 28. Brazil Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 29. Brazil Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 30. Brazil Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 31. Argentina Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 32. Argentina Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 33. Argentina Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 34. Argentina Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 35. Rest of South America Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 36. Rest of South America Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 37. Rest of South America Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 38. Rest of South America Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 39. Asia Pacific Brain Tumor Treatment, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 41. Asia Pacific Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 42. Asia Pacific Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 43. Asia Pacific Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 44. China Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 45. China Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 46. China Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 47. China Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 48. Japan Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 49. Japan Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 50. Japan Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 51. Japan Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 52. India Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 53. India Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 54. India Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 55. India Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 56. South Korea Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 57. South Korea Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 58. South Korea Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 59. South Korea Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 60. Taiwan Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 61. Taiwan Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 62. Taiwan Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 63. Taiwan Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 64. Australia Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 65. Australia Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 66. Australia Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 67. Australia Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 72. Europe Brain Tumor Treatment, by Country USD Million (2015-2020)
  • Table 73. Europe Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 74. Europe Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 75. Europe Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 76. Europe Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 77. Germany Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 78. Germany Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 79. Germany Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 80. Germany Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 81. France Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 82. France Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 83. France Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 84. France Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 85. Italy Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 86. Italy Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 87. Italy Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 88. Italy Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 89. United Kingdom Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 90. United Kingdom Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 91. United Kingdom Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 92. United Kingdom Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 93. Netherlands Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 94. Netherlands Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 95. Netherlands Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 96. Netherlands Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 97. Rest of Europe Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 98. Rest of Europe Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 99. Rest of Europe Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 100. Rest of Europe Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 101. MEA Brain Tumor Treatment, by Country USD Million (2015-2020)
  • Table 102. MEA Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 103. MEA Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 104. MEA Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 105. MEA Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 106. Middle East Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 107. Middle East Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 108. Middle East Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 109. Middle East Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 110. Africa Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 111. Africa Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 112. Africa Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 113. Africa Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 114. North America Brain Tumor Treatment, by Country USD Million (2015-2020)
  • Table 115. North America Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 116. North America Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 117. North America Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 118. North America Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 119. United States Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 120. United States Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 121. United States Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 122. United States Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 123. Canada Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 124. Canada Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 125. Canada Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 126. Canada Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 127. Mexico Brain Tumor Treatment, by Treatment USD Million (2015-2020)
  • Table 128. Mexico Brain Tumor Treatment, by End-user USD Million (2015-2020)
  • Table 129. Mexico Brain Tumor Treatment, by Diagnosis USD Million (2015-2020)
  • Table 130. Mexico Brain Tumor Treatment, by Tumor Type USD Million (2015-2020)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Brain Tumor Treatment: by Treatment(USD Million)
  • Table 142. Brain Tumor Treatment Surgery , by Region USD Million (2021-2026)
  • Table 143. Brain Tumor Treatment Radiation Therapy , by Region USD Million (2021-2026)
  • Table 144. Brain Tumor Treatment Radiosurgery , by Region USD Million (2021-2026)
  • Table 145. Brain Tumor Treatment Chemotherapy , by Region USD Million (2021-2026)
  • Table 146. Brain Tumor Treatment Targeted Drug Therapy , by Region USD Million (2021-2026)
  • Table 147. Brain Tumor Treatment: by End-user(USD Million)
  • Table 148. Brain Tumor Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 149. Brain Tumor Treatment Clinics , by Region USD Million (2021-2026)
  • Table 150. Brain Tumor Treatment Ambulatory Surgery Centres , by Region USD Million (2021-2026)
  • Table 151. Brain Tumor Treatment: by Diagnosis(USD Million)
  • Table 152. Brain Tumor Treatment Imaging Tests , by Region USD Million (2021-2026)
  • Table 153. Brain Tumor Treatment Neurological Exam , by Region USD Million (2021-2026)
  • Table 154. Brain Tumor Treatment Biopsy , by Region USD Million (2021-2026)
  • Table 155. Brain Tumor Treatment Others , by Region USD Million (2021-2026)
  • Table 156. Brain Tumor Treatment: by Tumor Type(USD Million)
  • Table 157. Brain Tumor Treatment Chordomas , by Region USD Million (2021-2026)
  • Table 158. Brain Tumor Treatment Craniopharyngiomas , by Region USD Million (2021-2026)
  • Table 159. Brain Tumor Treatment Astrocytomas , by Region USD Million (2021-2026)
  • Table 160. Brain Tumor Treatment Hemangioblastomas , by Region USD Million (2021-2026)
  • Table 161. Brain Tumor Treatment Others , by Region USD Million (2021-2026)
  • Table 162. South America Brain Tumor Treatment, by Country USD Million (2021-2026)
  • Table 163. South America Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 164. South America Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 165. South America Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 166. South America Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 167. Brazil Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 168. Brazil Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 169. Brazil Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 170. Brazil Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 171. Argentina Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 172. Argentina Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 173. Argentina Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 174. Argentina Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 175. Rest of South America Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 176. Rest of South America Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 177. Rest of South America Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 178. Rest of South America Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 179. Asia Pacific Brain Tumor Treatment, by Country USD Million (2021-2026)
  • Table 180. Asia Pacific Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 181. Asia Pacific Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 182. Asia Pacific Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 183. Asia Pacific Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 184. China Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 185. China Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 186. China Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 187. China Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 188. Japan Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 189. Japan Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 190. Japan Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 191. Japan Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 192. India Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 193. India Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 194. India Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 195. India Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 196. South Korea Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 197. South Korea Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 198. South Korea Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 199. South Korea Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 200. Taiwan Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 201. Taiwan Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 202. Taiwan Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 203. Taiwan Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 204. Australia Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 205. Australia Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 206. Australia Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 207. Australia Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 212. Europe Brain Tumor Treatment, by Country USD Million (2021-2026)
  • Table 213. Europe Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 214. Europe Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 215. Europe Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 216. Europe Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 217. Germany Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 218. Germany Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 219. Germany Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 220. Germany Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 221. France Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 222. France Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 223. France Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 224. France Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 225. Italy Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 226. Italy Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 227. Italy Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 228. Italy Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 229. United Kingdom Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 230. United Kingdom Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 231. United Kingdom Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 232. United Kingdom Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 233. Netherlands Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 234. Netherlands Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 235. Netherlands Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 236. Netherlands Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 237. Rest of Europe Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 238. Rest of Europe Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 239. Rest of Europe Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 240. Rest of Europe Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 241. MEA Brain Tumor Treatment, by Country USD Million (2021-2026)
  • Table 242. MEA Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 243. MEA Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 244. MEA Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 245. MEA Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 246. Middle East Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 247. Middle East Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 248. Middle East Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 249. Middle East Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 250. Africa Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 251. Africa Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 252. Africa Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 253. Africa Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 254. North America Brain Tumor Treatment, by Country USD Million (2021-2026)
  • Table 255. North America Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 256. North America Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 257. North America Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 258. North America Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 259. United States Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 260. United States Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 261. United States Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 262. United States Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 263. Canada Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 264. Canada Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 265. Canada Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 266. Canada Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 267. Mexico Brain Tumor Treatment, by Treatment USD Million (2021-2026)
  • Table 268. Mexico Brain Tumor Treatment, by End-user USD Million (2021-2026)
  • Table 269. Mexico Brain Tumor Treatment, by Diagnosis USD Million (2021-2026)
  • Table 270. Mexico Brain Tumor Treatment, by Tumor Type USD Million (2021-2026)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Tumor Treatment: by Treatment USD Million (2015-2020)
  • Figure 5. Global Brain Tumor Treatment: by End-user USD Million (2015-2020)
  • Figure 6. Global Brain Tumor Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 7. Global Brain Tumor Treatment: by Tumor Type USD Million (2015-2020)
  • Figure 8. South America Brain Tumor Treatment Share (%), by Country
  • Figure 9. Asia Pacific Brain Tumor Treatment Share (%), by Country
  • Figure 10. Europe Brain Tumor Treatment Share (%), by Country
  • Figure 11. MEA Brain Tumor Treatment Share (%), by Country
  • Figure 12. North America Brain Tumor Treatment Share (%), by Country
  • Figure 13. Global Brain Tumor Treatment share by Players 2020 (%)
  • Figure 14. Global Brain Tumor Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Brain Tumor Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Genentech U.S.A (United States) Revenue, Net Income and Gross profit
  • Figure 18. Genentech U.S.A (United States) Revenue: by Geography 2020
  • Figure 19. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 20. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 21. Roche Holding AG 9Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Roche Holding AG 9Switzerland) Revenue: by Geography 2020
  • Figure 23. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 29. Antisense Pharma (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Antisense Pharma (Australia) Revenue: by Geography 2020
  • Figure 31. Merck & Co.,Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co.,Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Macleods Pharmaceutical Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Macleods Pharmaceutical Limited (India) Revenue: by Geography 2020
  • Figure 35. Mankind Pharma (India) Revenue, Net Income and Gross profit
  • Figure 36. Mankind Pharma (India) Revenue: by Geography 2020
  • Figure 37. Global Brain Tumor Treatment: by Treatment USD Million (2021-2026)
  • Figure 38. Global Brain Tumor Treatment: by End-user USD Million (2021-2026)
  • Figure 39. Global Brain Tumor Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 40. Global Brain Tumor Treatment: by Tumor Type USD Million (2021-2026)
  • Figure 41. South America Brain Tumor Treatment Share (%), by Country
  • Figure 42. Asia Pacific Brain Tumor Treatment Share (%), by Country
  • Figure 43. Europe Brain Tumor Treatment Share (%), by Country
  • Figure 44. MEA Brain Tumor Treatment Share (%), by Country
  • Figure 45. North America Brain Tumor Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Genentech U.S.A (United States)
  • Bristol Myers Squibb (United States)
  • Roche Holding AG 9Switzerland)
  • AstraZeneca plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • Novartis AG (Switzerland)
  • Antisense Pharma (Australia)
  • Merck & Co.,Inc. (United States)
  • Macleods Pharmaceutical Limited (India)
  • Mankind Pharma (India)
Additional players considered in the study are as follows:
Dr. Reddys Laboratories Ltd. (India)
Select User Access Type

Key Highlights of Report


Sep 2021 249 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Brain Tumor Treatment Quantitative research analysis
Global Brain Tumor Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Genentech U.S.A (United States), Bristol Myers Squibb (United States), Roche Holding AG 9Switzerland), AstraZeneca plc (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Antisense Pharma (Australia), Merck & Co.,Inc. (United States), Macleods Pharmaceutical Limited (India) and Mankind Pharma (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Brain Tumor Treatment Market to reach USD Million by 2026.

Know More About Global Brain Tumor Treatment Report?

Have a Query? Click Here

Other Related Reports

Colorectal Cancer Comprehensive Study by Type (Lymphoma, Carcinoids, Turcot Syndrome, Adenocarcinoma, Juvenile Polyposis Coli, Peutz-Jeghers Syndrome (PJS), Familial Colorectal Cancer (FCC), Gastroin...
$ 3750
Extremity Reconstruction Comprehensive Study by Type (Upper Extremity (Shoulder Reconstruction(Partial Shoulder Replacement, Total Standard Replacement, Stemless Total Shoulder Replacement, Total Rev...
$ 3750
Pediatric Brain Tumor Comprehensive Study by Type (Gliomas, Mixed neuronal-glial tumors, Embryonal tumors, Choroid plexus papilloma/carcinoma, Non-neuroepithelial tissue tumors, Meningeal Tumors, Oth...
$ 3500
Head and Neck Cancer Diagnostics Comprehensive Study by Type (Diagnostic imaging equipment, Endoscopy screening equipment, Bioscopy screening tests, Blood tests, Dental diagnostic), Application (Hosp...
$ 3750
Implantable Heart Pacemaker Comprehensive Study by Type (Single Chamber, Dual-Chamber, Biventricular Pacemaking), Application (Heart Block, Sick Sinus Syndrome, Diagnosing Heart Diseases, Others), Pa...
$ 3650
Orthopaedics Comprehensive Study by Application (Fracture Management, Joint Replacement, Orthopedic Surgery, Pediatric Assessment, Pediatric Assessment), Area of Treatment (Trauma, Spine, Knee, Hip),...
$ 3350